Literature DB >> 6462108

Lack of in vitro activity of cefoxitin, cefamandole, cefuroxime, and piperacillin against Chlamydia trachomatis.

W R Bowie.   

Abstract

Newer penicillins and cephalosporins are being evaluated in many infections. One of these infections, acute pelvic inflammatory disease, can be caused by Chlamydia trachomatis. This study demonstrated that cefoxitin, cefamandole, cefuroxime, and piperacillin had no effective in vitro activity against C. trachomatis.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6462108      PMCID： PMC181884          DOI： 10.1128/AAC.21.2.339

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Emergence of rifampin-resistance in Chlamydia trachomatis.

Authors:  H Keshishyan; L Hanna; E Jawetz
Journal:  Nature       Date:  1973-07-20       Impact factor: 49.962

Review 2.  Salpingitis: overview of etiology and epidemiology.

Authors:  K K Holmes; D A Eschenbach; J S Knapp
Journal:  Am J Obstet Gynecol       Date:  1980-12-01       Impact factor: 8.661

3.  Antimicrobial drug susceptibility of 15 strains of Chlamydia trachomatis recently isolated from cases of non-gonococcal urethritis, in Italy.

Authors:  R Cevenini; M P Landini; M Donati; F Rumpianesi
Journal:  J Antimicrob Chemother       Date:  1980-03       Impact factor: 5.790

4.  Activity of antimicrobials against Chlamydia trachomatis in vitro.

Authors:  G L Ridgway; J D Oriel
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

5.  Treatment of nongonococcal urethritis with rifampicin as a means of defining the role of Ureaplasma urealyticum.

Authors:  E D Coufalik; D Taylor-Robinson; G W Csonka
Journal:  Br J Vener Dis       Date:  1979-02

6.  Relative resistance to erythromycin in Chlamydia trachomatis.

Authors:  A Mourad; R L Sweet; N Sugg; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

7.  Treatment of obstetric and gynecologic infections with cefamandole.

Authors:  F G Cunningham; L C Gilstrap; S S Kappus
Journal:  Am J Obstet Gynecol       Date:  1979-03-15       Impact factor: 8.661

8.  Prediction of efficacy of antimicrobial agents in treatment of infections due to Chlamydia trachomatis.

Authors:  W R Bowie; C K Lee; E R Alexander
Journal:  J Infect Dis       Date:  1978-11       Impact factor: 5.226

9.  Differential response of chlamydial and ureaplasma-associated urethritis to sulphafurazole (sulfisoxazole) and aminocyclitols.

Authors:  W R Bowie; J F Floyd; Y Miller; E R Alexander; J Holmes; K K Holmes
Journal:  Lancet       Date:  1976-12-11       Impact factor: 79.321

10.  Cefoxitin: single-agent treatment of mixed aerobic-anaerobic pelvic infections.

Authors:  R L Sweet; W J Ledger
Journal:  Obstet Gynecol       Date:  1979-08       Impact factor: 7.661
View more
  5 in total

1.  In vitro activity of clavulanic acid, amoxicillin, and ticarcillin against Chlamydia trachomatis.

Authors:  W R Bowie
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

2.  In vitro activity of temocillin (BRL 17421) against Chlamydia trachomatis.

Authors:  K H Tjiam; B Y van Heijst; T van Joost; E Stolz; M F Michel
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

Review 3.  Role of cephalosporins in gonorrhoea and other sexually transmitted diseases.

Authors:  I Phillips
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  In vitro activity of a group of broad-spectrum cephalosporins and other beta-lactam antibiotics against Chlamydia trachomatis.

Authors:  M R Hammerschlag; A Gleyzer
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

5.  In Vitro Susceptibility Testing of Clinical Isolates of Chlamydia trachomatis.

Authors:  M G Martens; S Faro; M Maccato; G Riddle; H Hammill; Y Wang
Journal:  Infect Dis Obstet Gynecol       Date:  1993
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.